It is known that compared to MSS colon cancer, colon cancer with mutations in the exonuclease domain in POLE has a higher mutational burden, higher expressions of immune checkpoints such as PD-L1, and a higher expression of T-cell markers [14,29]. This evidence concerns the gene POLE and colonic neoplasm.